Oklo rated Speculative Buy for its innovative nuclear reactor tech and upcoming milestones despite current losses.

Oklo has received a Speculative Buy rating due to its unique fast-neutron, sodium-cooled Aurora reactor design, which aims to reduce construction and operational costs. Although the company is currently deeply unprofitable and pre-commercial, key upcoming catalysts include the Groves Isotopes test reactor reaching criticality and the start of revenue from medical isotope production expected by the end of this year. The company's valuation is heavily milestone-driven, with risks including regulatory delays and competition from renewable energy and battery storage technologies.